Physician profile
Lawrence Blacher
NPI 1487610515
$2,267.84
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $344 · 2021: $89.08 · 2022: $692 · 2023: $14.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $447.10 | 2019-2022 | |
| Medtronic Vascular, INC. | $409.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $219.36 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $186.06 | 2019-2022 | |
| Amarin Pharma, INC. | $163.89 | 2019-2020 | |
| Amgen INC. | $155.22 | 2019-2022 | |
| Novo Nordisk INC | $135.30 | 2022-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $119.46 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $107.52 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $81.50 | 2019-2020 | |
| Akcea Therapeutics, INC. | $68.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $63.33 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $48.07 | 2019 | |
| Covidien LP | $18.32 | 2019 | |
| Amryt Pharma Holdings LTD | $17.25 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.91 | 2020 | |
| Allergan, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Blacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.